Network Systems Science & Advanced Computing Biocomplexity Institute & Initiative University of Virginia

Foresight and Analysis of Infectious Disease Threats to Virginia's Public Health

March 7th, 2024

(data current to February 29th – March 6th) Biocomplexity Institute Technical report: TR BI-2024-20

UNIVERSITY of VIRGINIA

BIOCOMPLEXITY INSTITUTE

biocomplexity.virginia.edu

About Us

- Biocomplexity Institute at the University of Virginia
 - Using big data and simulations to understand massively interactive systems and solve societal problems
- Over 20 years of crafting and analyzing infectious disease models
 - Pandemic response for Influenza, Ebola, Zika, and others



Points of Contact

Bryan Lewis brylew@virginia.edu

Srini Venkatramanan srini@virginia.edu

Madhav Marathe marathe@virginia.edu

Chris Barrett ChrisBarrett@virginia.edu

Model Development, Outbreak Analytics, and Delivery Team

Abhijin Adiga, Aniruddha Adiga, Hannah Baek, Chris Barrett, Parantapa Bhattacharya, Chen Chen, Da Qi Chen, Jiangzhuo Chen, Baltazar Espinoza, Galen Harrison, Stefan Hoops, Ben Hurt, Gursharn Kaur, Brian Klahn, Chris Kuhlman, Bryan Lewis, Dustin Machi, Madhav Marathe, Sifat Moon, Henning Mortveit, Mark Orr, Przemyslaw Porebski, SS Ravi, Erin Raymond, Samarth Swarup, Pyrros Alexander Telionis, Srinivasan Venkatramanan, Anil Vullikanti, Andrew Warren, Amanda Wilson, Dawen Xie



Overview

• **Goal**: Understand impact of current and emerging Infectious Disease threats to the Commonwealth of Virginia using modeling and analytics

• Approach:

- Provide analyses and summaries of current infectious disease threats
- Survey existing forecasts and trends in these threats
- Analyze and summarize the current situation and trends of these threats in the broader context of the US and world
- Provide broad overview of other emerging threats



Key Takeaways

COVID-19 indicators remain elevated, trends are mixed between steady and decline

- Hospital admissions and Visits with Diagnosed COVID are higher than they were at this point last year
 - Hospital admissions peak was ~20% lower than last year, but the peak this year is broader.
- Wastewater continues to show high viral loads, though may be receding
- Together this suggest continued plateaus in activity with likely decline in coming weeks.

Influenza is remains elevated in VA and across the US

RSV hospitalizations have reduced to minimal activity



COVID-19 Surveillance



District Diagnosed COVID Trajectories – last 10 weeks

Status	Number of Districts		
	Current Week	Last month	
Declining	17	9	
Plateau	16	24	
Slow Growth	2	2	
In Surge	0	0	

Curve shows smoothed Emergency Dept and Urgent Care visits with Diagnosed COVID-19 rate (per 100K) in each District

West Piedmont - Plate

jan 2024

386 2024

Trajectories of states in label & chart box Curve colored by Reproductive number

jan 2024



UNIVERSITY of VIRGINIA

3024

District Hospital Trajectories – last 10 weeks

Rt estimates from EpiNow2



Hospitalization by county inferred from Facility data mapped to counties through Hospital Referral Regions.

As of Feb 24th



2024-02-24

Curve shows smoothed hospitalization rate (per 100K) by district Hosp rate curve colored by R_e number



Blue Ridge - Platea

Hospitalizations in VA by Age

Age distribution in hospitals showing slight shift towards younger age groups

- Overall hospitalizations stable across all age groups
- Pediatric hospitalizations remain high ulletcompared to summer and fall



Pediatric Hospitalizations by Age (0-17yo)





Note: These data are lagged and based on HHS hospital reporting



United States Hospitalizations

Status Current Week Declining 25 Plateau 27 **Slow Growth** 1 In Surge 0



3/8/2024

COVID-19 Hospitalizations – Epidemic Growth



Estimating Daily Reproductive Number – EpiNow2 estimation R_e per confirmed

Region	Reproductive number estimate	Credible Interval	Trend forecast
State-wide	0.89	(0.67 – 1.1)	Likely decreasing
Central	0.94	(0.84 – 1)	Likely decreasing
Eastern	0.95	(0.87 – 1)	Likely decreasing
Northern	0.95	(0.82 – 1.1)	Likely decreasing
Northwest	0.92	(0.77 – 1)	Likely decreasing
Southwest	0.97	(0.87 – 1.1)	Likely decreasing

Reproductive Estimate Summary, per data as of March 2nd, 2024

Methodology

- Sam Abbott, Joel Hellewell, Katharine Sherratt, Katelyn Gostic, Joe Hickson, Hamada S. Badr, Michael DeWitt, Robin Thompson, EpiForecasts, Sebastian Funk (2020). EpiNow2: Estimate Real-Time Case Counts and Time-Varying Epidemiological Parameters. doi:10.5281/zenodo.3957489.
- COVID disease model parameters (including generation time and delay distributions) per CDC CFA blog: <u>https://www.cdc.gov/forecast-outbreak-analytics/about/technical-blog-rt.html#anchor_01204</u>
- Uses confirmation date but report date biases are accounted for; estimated date of infection is inferred using Bayesian smoothing techniques and used to produce Rt estimates.
- Source data: <u>https://data.virginia.gov/dataset/vdh-covid-19-publicusedataset-cli-by-healthdistrict</u>

EpiNow2 home: https://epiforecasts.io/EpiNow2/

R_e per confirmed ED diagnosis (last 6 months)





Wastewater Monitoring – NWSS

Wastewater provides a coarse estimate of COVID-19 levels in communities

- VA back to "Moderate" after being "Very High" due to artifacts last week
- Pervious, well observed, levels below region and national levels



Week Ending



Week Ending







Wastewater Monitoring – VA Sites

Wastewater provides COVID-19 levels in communities which correlate to disease burden



ED & UC Visits with Diagnosed COVID-19

National Syndromic Surveillance Program (NSSP) reports diagnosed COVID-19 from multiple healthcare settings

- Week ending March 5^h, 2024
- Diagnosed visits are a smoother more specific indicator than COVID-like Illness
- COVID-19 Diagnosed visits show signs of further decline after a period so slowed decreases





MUNIVERSITY of VIRGINIA

Current COVID-19 Hospitalization Forecast

Statistical models for submitting to CDC COVID Forecasting Hub

 Uses a variety of statistical and ML approaches to forecast weekly hospital admissions for the next 4 weeks for all states in the US







COVID-19 Spatial Epidemiology



ZIP Code Level Case Rates Since Last Meeting

New cases per 100k in the last four weeks

- Divide rates by four to calculate average weekly incidence.
- No change in color scale from last meeting.
- Case rates continue to decline across the Commonwealth.
- Rates remain elevated in • far Southwest Virginia, and in a few isolated Southside ZIP codes.
- No ZIP codes with prisons appear in this week's top 10.

Rank	Zip Code	Name	Rate	
1	23924	Chase City	9,260	
2	24226	Clinchco	8,930	
3	23413	Nassawadox	8,550	
4	24171	Stuart	8,450	
5	24656	Vansant	7,970	
6	24319	Chilhowie	7,780	
7	24283	Saint Paul	7,540	
8	24201	Bristol	6,890	
9	22560	Tappahannock	6,820	
10	24641	Richlands	6,630	
Only includes zips with pop ≥ 1000 and no supp. data. * Denotes zip codes with state prisons.				



Based on Spatial Empirical Bayes smoothed case rates, with an 8:1 ascertainment ratio, for four weeks ending 2024-02-06.

UNIVERSITY of VIRGINIA

BIOCOMPLEXITY INSTITUTE

Case Rate

Risk of Exposure / Spatial Clusters and Hot Spots

Case rates since last meeting by ZIP code used to calculate risk of encountering someone infected in a gathering of randomly selected people and find spatial hot spots

- **Group Size**: Assumes **8 undetected infections** per confirmed case (ascertainment rate from recent seroprevalence survey) and shows minimum size of a group with a 50% chance an individual is infected by ZIP code (e.g., in a group of 29 in Chase City, there is a 50% chance someone will be infected).
- **Spatial Clustering**: Getis-Ord Gi* based hot spots compare clusters of ZIP codes with four-week case rates higher than nearby ZIP codes to identify larger areas with statistically significant deviations. SaTScan was used to corroborate this analysis and determine relative risk for identified clusters.



COVID-19 among Healthcare Workers

COVID-19 case rates for the public and for healthcare workers (HCW) were compared to find regions where HCW suffered unusually high burdens of disease

- HCW Rate: Case rate among health care workers (HCW) over a four-week period ending January 8, 2024.
- HCW Ratio: Case rate among health care workers (HCW) over the same period using patient facing healthcare workers as the numerator, and the population's case rate as the denominator.
- The healthcare case to public case ratio is well below one in most counties. Only a few show an elevation in HCW cases and a high healthcare worker to public case ratio (e.g. Patrick, Henry, and Franklin Counties).



Emergency Department Diagnosis Rate – COVID-19

Southside and Far SW report the highest rates, though these are only about half what they were at last report (now 3%). Far SW and the Roanoke-Lynchburg area report increases.



COVID-19 Genomic Update



SARS-CoV2 Variants of Concern

Nowcast Estimates in HHS Region 3

Emerging variants have potential to continue to alter the future trajectories of pandemic and have implications for future control

• Variants have been observed to: increase transmissibility, increase severity (more hospitalizations and/or deaths), and limit immunity provided by prior infection and vaccinations

Weighted Estimates in HHS Region 3 for 2-Week Periods in 11/12/2023 -

3/2/2024 for 2/18/2024 - 3/2/2024 Hover over (or tap in mobile) any lineage of interest to see the amount of uncertainty in that lineage's estimate. Region 3 - Delaware, District of Columbia, Maryland Pennsylvania, Virginia, and West Virginia Nowcast: Model-based Weighted Estimates: Variant proportions based on reported genomic projected estimates of WHO label Lineage # %Total 95%P sequencing results variant proportions Omicron JN. 90 86.2-93.19 **JN 1 13** 1 1-11 9% 4 1% JN 1 18 3.8% 1.6-8.2% BA.2.86 0.4% 0.2-0.8% HV.1 0.3% 0.2-0.5% JG.3 0.2% 0.1-0.3% JD.1.1 2 80% 0.2% 0.1-0.2% **BA.2** 0.1% 0.0-0.2% HK.3 0.1% 0.0-0.1% EG.5 0.0% 0.0-0.0% B 60% XBB 0.0% 0.0-0.0% GE.1 0.0% 0.0-0.0% EG.5.1.8 0.0% 0.0-0.0% IN.1 XBB.1.9.1 0.0% 0.0-0.0% ₽ 40% FL.1.5.1 0.0% 0.0-0.0% JE 1 0.0% 0.0-0.0% XBB.1.5.70 0.0% 0.0-0.0% XBB 1.16.15 0.0% 0.0-0.0% XBB.1.16.6 0.0% 0.0-0.0% 20% XBB.2.3 0.0% 0.0-0.0% XBB.1.16.11 0.0% 0.0-0.0% GK.1.1 0.0% 0.0-0.0% HF.1 0.0-0.0% 0.0% 0% GK.2 0.0% 0.0-0.0% 2/3/24 XBB.1.9.2 0.0% 0.0-0.0% XBB.1.16 0.0% 0.0-0.0% XBB.1.5 0.0% 0.0-0.0% 0.0% 0.0-0.0% EG 6 1 XBB 1 42 2 0.0% 0.0-0.0% XBB.1.16.1 0.0% 0.0-0.0% Other' 0.2-1.3% Collection date, two-week period ending

* Enumerated lineages are US VOC and lineages circulating above 1% nationally in at least one 2-week period. "Other" represents the aggregation of lineages which are circulating <1% nationally during all 2-week periods displayed # While all lineages are tacked by CDC, those named lineages not enumerated in this graphic are aggregated with their parent lineages, based on Pango lineage definitions, described in more detail here: https://www.pango-ineaded/their.com/end/tacked/tack



Omicron Updates*

- JN.1 and descendants completely saturate
- Lineage HV.1 (XBB.1.9*) down to 0.3% from 1%
- Other BA.2.86, JD.1.1, JG.3 remain top variants but are below 1%

*percentages are CDC NowCast Estimates



SARS-CoV2 Variants of Concern

A variety of co-circulating variants have emerged with multiple recombinations between JN.1 lineages and other XBB lineages

B.1.1.529

Data shown as of February 21st, 2024. Proportions are given for lineages that are observed in sequences with a specimen date between 5 February 2024 and 16 February 2024.

https://www.gov.uk/government/publications/sars-cov-2-genome-sequence-prevalence-andgrowth-rate/sars-cov-2-genome-sequence-prevalence-and-growth-rate-update-21-february-2024

BM.1.1 BJ.1 XBB.2.3 XBB.2.3.10 GE.1 JN.1.9 [1.5%] XBB.2 GE.1.2 GE.1.2.1 BA.2.10.1 BA.2.10 XBB.1.9.2 XBB.1.9 JN.1.8 [2.9%] **BM.1** [2.1%] EG.5 EG.5.1 BM.1.1.1 XBB.1 JN.1.7 [0.6%] [3.5%] [0.9%] XBB.1.5.102 XBB.1.5 JN.6 BA.2.75 BA.2.75.3 [0.6%] JD.1 BA.2 XDD.1 JN.1.5 JN.1.9.1 JD.1.1 EG.5.1.3 [0.3%] [0.3%] [1.2%] [1.5%] [0.3%] JN.3 XBB.1.16 XBB.1.16.11 [0.6% [0.3%] XDK JN.1.4 JN.1.1.1 EG.5.1.1 [15%] 0.3% XDN [0.3%] JN.2 BA.2.86.1 [0.3%] BA 2.86 [1.8%] [3.2%] JN.1.22 [2.9%] JN.1.19 JN.1 [0.6%] [47.5%] JN.1.18 [2.1%] JN.1.1 [3.5%

SARS-CoV2 Omicron Sub-Variants

Enabled by data from **GISAID**

covSPECTRUM



SARS-CoV2 Omicron Sub-Variants



Enabled by data from **GISAID**

BA.2.86*

JN.1*

DV.7.1*

XAY*

Global SARS-CoV2 Variant Status

Traveller Surveillance

Variants Detected, by Collection Week



Positivity Rate for Pooled Samples, by Collection Week





https://cov.lanl.gov/components/sequence/COV/sparks.comp https://covid.cdc.gov/covid-data-tracker/#traveler-genomic-surveillance

Global SARS-CoV2 Variant Status



Logit transform Daily raw data Weekly raw data

Clade frequencies over time

Each line represents the estimated frequency of a particular clade through time. Equivalent Pango lineage is given in parenthesis, eg clade 23A (lineage XBB.1.5). Only locations with more than 100 sequences from samples collected in the previous 150 days are included. Results last updated 2024-03-05.





Lineage growth advantage

These plots show the estimated growth advantage for given Pango lineages relative to lineage JN.1. This describes how many more secondary infections a variant causes on average relative to lineage JN.1. Vertical bars show the 95% HPD. The "hierarchical" panel shows pooled estimate of growth rates across different locations. Results last updated 2024-03-05.

 ● DV.7.1
 ● DV.7.1.4
 ● BA.2.86
 ● JN.1.1
 ● JN.1.2
 ● JN.1.4
 ● JN.1.4.2
 ● JN.1.4.3
 ● JN.1.6

 ● JN.1.7
 ● JN.1.8.1
 ● JN.1.9
 ● JN.1.18
 ● JN.1.22
 ● JN.2
 ● JN.2.5
 ● JN.3
 ● JN.3

 ● JRB.1
 > XBB.1.5
 ● GK.1
 ● GK.2
 ● JD.1.1
 ● JD.1.1.1
 ● JD.1.1.8
 ■ XBB.1.9.1
 ● FL.1.5.1

 ● KC.1
 ● FL.15
 ■ XBB.1.9.2
 ● GG.5.1.1
 ● IK.3.2
 ● HK.13
 ● HK.20.1

 ● HK.26
 ● EG.5.1.3
 ● JG.3.1
 ● JG.3.2
 ● EG.5.1.4
 ● JJ.1
 ● EG.5.1.6
 ● HV.1
 ● HV.1.1

 ● HV.1.2
 ● HV.1.4
 ● HV.1.5
 ● HV.1.6
 ● KL1
 ● EG.5.1.8
 ● EG.5.1.1.0
 ● HV.1
 ● EG.5.1.1
 ● HK.9
 ● GK.1.1
 ● EG.5.1.1
 ● HK.9
 ● XBB.1.16.1
 ● XBB.1.16.1
 ● XBB.1.16.1
 ● KL1
 ● JF.1
 ● JF.1

Wastewater Monitoring – NWSS

Wastewater provides a coarse estimate of COVID-19 levels in communities

- VA back to "Moderate" after being "Very High" due to artifacts last week
- Pervious, well observed, levels below region and national levels



Week Ending



Week Ending







National Wastewater Variant Status





https://www.cdc.gov/nwss/rv/COVID19-variants.html https://biobot.io/data/

Virginia Regional Wastewater Variant Status (median)







Far Southwest COVID-19 Genomic Prevalence over Time B.1.1.529 1.0 BA.2.86 FL.1 HK.3 0.8 HV.1 Other XBB.1.16 Prevalence 6.0 XBB.1.5 XBB.1.9 XBB.2.3 0.2 -0.0 Aug Sep Oct Nov Dec Jan 2024 Feb





Eastern COVID-19 Genomic Prevalence over Time 1.0 -BA.2.75 BA.2.86 FL.1 HK.3 0.8 HV.1 Other Prevalence XBB.1.16 XBB.1.5 XBB.1.9 XBB.2.3 0.2 0.0 2023-09 2023-20 2023-11 2023-12 2023-08 2024-01 2024-02

Data updated through 12/24

Virginia Regional Population-Weighted Wastewater Variant Status





Near Southwest COVID-19 Genomic Pop-Weighted Prevalence







Data updated through 12/24

Pandemic Pubs (March 7th, 2024)

Long COVID Cognitive Effect: Study of 800K in England, provided a cognitive assessment online and measured performance over time for those infected with COVID-19. Those with short times to resolution of symptoms experienced lower overall deficits. (New England Journal of Medicine, Feb 2024)



In this observational study, we found objectively measurable cognitive deficits that may persist for a year or more after Covid-19. We also found that participants with resolved persistent symptoms had small deficits in cognitive scores, as compared with the no-Covid-19 group, that were similar to those in participants with shorter-duration illness. Early periods of the pandemic, longer illness duration, and hospitalization had the strongest associations with global cognitive deficits.

Pandemic Pubs (March 7th, 2024)

Long COVID Prevented by Vaccination: First of 2 studies summarized, Long COVID prevalence was 40-60% lower among vaccinated vs. unvaccinated in Michigan. Second study shows protective effect for adolescents against Long COVID across successive waves of SARS-CoV2 variants. (Eric Topol, Ground Truths, Feb 2024)

Two New Reports of Vaccination Protection Vs Long Covid

From a study in the Annals of Epidemiology, Michiganders derived an important protective benefit against Long Covid: Long COVID prevalence was 40-60% lower among adults vaccinated (vs. unvaccinated) prior to their COVID-19. This level of protection is consistent with many recent reports and has not been emphasized enough regarding an added benefit of booster shots. The data were previously reviewed on Ground Truths <u>here</u>.

And a <u>new preprint report on protection in children and adolescents</u> which looked at different variants (Delta and Omicron) and cause and effect relationship for direct benefit of vaccination, summarized in the Table below. More protection was found in teens than children with the range of 60 to 75%.

Vaccine Effectiveness (in $\%)$ and 95 CI	Direct Effect	Indirect Effect
Delta stud	ly in adolescents	
95.4% (90.9, 97.7)	1.08 (0.75, 1.55)	0.04 (0.03, 0.05)
Omicron	study in children	
60.2% (40.3, 73.5)	1.24 (0.92, 1.66)	0.31 (0.23, 0.42)
Omicron st	udy in adolescents	
75.1% (50.4, 87.5)	0.91 (0.69, 1.19)	0.21 (0.16, 0.27)

Solving the puzzle of Long Covid

Long Covid provides an opportunity to understand how acute infections cause chronic disease

ZIYAD AL-ALY AND ERIC TOPOL Authors Info & Affiliations

SCIENCE · 22 Feb 2024 · Vol 383, Issue 6685 · pp. 830-832 · DOI: 10.1126/science.adl0867

Essay in <u>Science</u> advocating for addressing Long COVID <u>https://www.science.org/doi/10.1126/science.adl0867</u>



Pandemic Pubs (March 7th, 2024)

controls.

Hyper-Vaccination: German man received 217 vaccinations over the course of 2.5 years. This Hyper-vaccination led to no adverse events and increased the quantity of antibodies and T-cells and did not negatively effect the quality of his immune response. (Lancet, March 2024)



(i) The Despicit Construction of Despicit Con

Influenza Update



Current Influenza Situation – ILI Activity

All regions remain above threshold and many are steady

- Virginia remains a "High" level of Influenza activity
- National ILI activity has been at a steady high level for 6 weeks 2023-24 Influenza Season Week 8 ending Feb 24, 2024







Low

Cumulative

A (H1) - 0

A (H3) - 122

H3N2y - 0 B (Victoria Lineage) - 115

Most Recent 3 weeks Number of Influenza Positive Test

A (Unable to Subtype) - 0

B (Yamagata Lineage) - 0

No Data/Small Data Sample

A (Subtyping not Performed) - 42 B (Lineage Unspecified) - 17

A (H1N1)pdm09 - 97





BIOCOMPLEXITY INSTITUTE

FluView Surveillance

High

High

High

Low

Low

Region 3



Virginia (ED & UC Visits – Feb24, 2024)

Percent of Medical Visits for Influenza-like Illness by Flu Season ILI data shown on this graph are from EDs and urgent cares that currently report data to VDH. Data from facilities that reported in previous sea: longer report to VDH are not included Flu Season 2023-24 8.0% 2022-23 2021-22 2020-21 6.0% 2019-20 4.09

Intensity Level by Region, Week ending February 24, 2024



36

Influenza Hospitalizations – Epidemic Growth



Emergency Department Diagnosis Rate – Influenza

Flu diagnoses are still highest in the New River Valley, with rates rivaling last month's reports (over 6%). Most of the Commonwealth reported increases from the week prior.



Influenza Forecasts – Hospitalization Admissions



Virginia

National Flu Hospital Admissions Weekly hospital admissions Last update: March 2nd, 2024



Current Influenza Hospitalization Forecast

Statistical models for submitting to CDC Influenza Forecasting Hub

 Uses a variety of statistical and ML approaches to forecast weekly hospital admissions for the next 4 weeks for all states in the US
 Virginia

Hospital Admissions for Influenza and Forecast for next 4 weeks (CDC Influenza Ensemble)

From February 28th

CDC Flu Activity Surveillance

https://www.cdc.gov/flu/weekly/fluactivitysurv.htm











Current RSV Situation – Hospitalization Rates (RSV-Net)

Maryland (RSV-Net)

Tennessee (RSV-Net)



Surveillance data as of:

2/10 (last solid data)2/24 (last recent but likely to be updated)





Emergency Department Diagnosis Rate – RSV

RSV rates are so low that a different color scale was required for maps. No counties report a diagnosis rate higher than 0.28%. Most counties continue to report weekly decreases.



Respiratory Illness Combined Update



Combined Respiratory Illness Viruses - Wastewater

Regional Flu and RSV Wastewater Concentrations





https://biobot.io/data/



Combined Respiratory Illness Viruses – NSSP VA ED Visit





Data as of February 24th, 2024

MUNIVERSITY of VIRGINIA

Key Takeaways

COVID-19 indicators remain elevated, trends are mixed between steady and decline

- Hospital admissions and Visits with Diagnosed COVID are higher than they were at this point last year
 - Hospital admissions peak was ~20% lower than last year, but the peak this year is broader.
- Wastewater continues to show high viral loads
- Together this suggest continued plateaus in activity with likely decline in coming weeks.

Influenza is remains elevated in VA and across the US

RSV hospitalizations have reduced to minimal activity



Questions?

Points of Contact

Bryan Lewis brylew@virginia.edu

Srini Venkatramanan srini@virginia.edu

Madhav Marathe marathe@virginia.edu

Chris Barrett ChrisBarrett@virginia.edu

Biocomplexity COVID-19 Response Team

Aniruddha Adiga, Abhijin Adiga, Hannah Baek, Chris Barrett, Golda Barrow, Richard Beckman, Parantapa Bhattacharya, Jiangzhuo Chen, Clark Cucinell, Patrick Corbett, Allan Dickerman, Stephen Eubank, Stefan Hoops, Ben Hurt, Ron Kenyon, Brian Klahn, Bryan Lewis, Dustin Machi, Chunhong Mao, Achla Marathe, Madhav Marathe, Henning Mortveit, Mark Orr, Joseph Outten, Akhil Peddireddy, Przemyslaw Porebski, Erin Raymond, Jose Bayoan Santiago Calderon, James Schlitt, Samarth Swarup, Alex Telionis, Srinivasan Venkatramanan, Anil Vullikanti, James Walke, Andrew Warren, Amanda Wilson, Dawen Xie

